Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, ...

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, German ...

“Our findings suggest that GLP-1 receptor agonists may offer benefits beyond their effects on weight and glucose control, ...

Pfizer is paying over $7 billion to buy clinical-stage biotech Metsera. This gives it a wedge into the hottest segment of the pharma industry. Yet, shares of the giant drugmaker remain at depressed ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...

Several GLP-1 pills are in development. Here's when you can expect this new wave of these popular weight-loss medications.